ReviewHuman vaccines & immunotherapeutics2023
Driving more WHO-recommended vaccines in the National Immunization Program: Issues and challenges in China.
Review in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Vaccination coverage and influencing factors of four non‑National Immunization Program vaccines: A cross‑sectional survey among children aged 1‒6 years in Beijing, China.Human vaccines & immunotherapeutics · 2026Article
- Comparative analysis of adverse events following immunization with DTaP vaccine in children before and after immunization schedule adjustment.Human vaccines & immunotherapeutics · 2026Article
- Spatial accessibility analysis of vaccination units in Gansu Province, China (2025).Human vaccines & immunotherapeutics · 2026Article
- Economic evaluation of national immunization program vaccines in China: a systematic review.Health economics review · 2026Review
- Article
- Analysis of epidemiological characteristics and vaccine effectiveness of pertussis in Linping District, China.Frontiers in public health · 2026Article
- Changed Trends in Utilization and Substitution Pattern of Non-National Immunization Program Vaccines in Central China, 2011-2024.Vaccines · 2025Article
- Service delivery costs of vaccination at health facilities in Guangzhou, China.Human vaccines & immunotherapeutics · 2025Article
- Parents' preference for the inclusion of pediatric vaccines in the Chinese National Immunization Program: A discrete choice experiment.Human vaccines & immunotherapeutics · 2025Article
- Adverse Events FollowingVaccines · 2025Article
- Financing the introduction of new vaccines to the national immunisation programme in China: challenges and options for action.BMJ global health · 2025Review
- The intention and influencing factors of human papillomavirus vaccination among female students in the secondary vocational schools in East China: a cross-sectional study.Frontiers in public health · 2025Article
- Public Preference and Priorities for Including Vaccines in China's National Immunization Program: Discrete Choice Experiment.JMIR public health and surveillance · 2024Article
- The equity road ahead for financing non-national immunization program vaccines in China: challenges and opportunities from a qualitative study.International journal for equity in health · 2024Article
- Analysis of data from two influenza surveillance hospitals in Zhejiang province, China, for the period 2018-2022.PloS one · 2024Article
- Respiratory pathogenic microbial infections: a narrative review.International journal of medical sciences · 2024Review
- Surveillance for adverse events following immunization with DTaP-containing combination vaccines in Linping, China, 2019-2022.Frontiers in public health · 2024Article
- Accelerating into Immunization Agenda 2030 with momentum from China's successful COVID-19 vaccination campaign during dynamic COVID Zero.Infectious diseases of poverty · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
WHO-recommended vaccines substantially prevent and control vaccine-preventable diseases (VPDs), but their inclusion differs among countries and regions. We reviewed the application for WHO-recommended vaccines in China and described the concerns and obstacles in driving the inclusion of more vaccines into China's NIP, including immunization strategies, financial barriers, vaccination services, and behavioral and social supply-side and demand-side factors. China has made significant efforts, however, they may not be sufficient until the inclusion of more WHO-recommended vaccines in the National Immunization Program (NIP), ensuring that the vaccination encompasses the whole life course of individuals, establishment of more trustworthy vaccination finance and procurement, increasing vaccine development, optimizing vaccine demand forecasts, improving the accessibility and equity of vaccination services, capturing the key points of behavioral and social drivers of vaccination on the demand side, and establishing holistic prevention and control from a public health perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.